Canadian Considerations: Access and Regulations Understanding the regulatory landscape helps Canadian researchers and biohackers navigate BPC-157 access appropriately
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
Over several weeks: Continued healing, progressive reduction in chronic symptoms, improved tissue function With ongoing treatment: Sustained benefits, better quality of life, restored function you thought you'd lost Everyone's healing timeline is different
Targeted Defense - Proactive Prevention -Enhanced Immunity - Convenient and Effective: Don't leave your health to chance take proactive steps to protect yourself against germs and viruses with our Eradicate IV Treatment
Cathy Testimonials It was great having options close to work and home